Fulvestrant

drugbox
IUPAC_name = 13-methyl-7- [9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl] - 7,8,9,11,12,13,14,15,16, 17-decahydro- 6"H"-cyclopenta [a] phenanthrene-3,17-diol

---

CAS_number = 129453-61-8
ATC_prefix = L02
ATC_suffix = BA03
ATC_supplemental =
PubChem = 104741
DrugBank = APRD00654
C = 32 | H = 47 | F = 5 | O = 3 | S = 1
molecular_weight = 606.772 g/mol
bioavailability =
protein_bound = 99%
metabolism =
elimination_half-life = 40 days
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category = D
legal_AU =
legal_UK =
legal_US =
legal_status = Rx only
routes_of_administration = Intramuscular injection

Fulvestrant, also known as ICI 182,780, and "Faslodex" is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. [S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." "Mol Cell Endocrinol." 2005 Jul 15;239(1-2):27-36.] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Clinical uses

Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

External links

* [http://www.faslodex.com Faslodex product website]
* [http://www.astrazeneca-us.com/pi/faslodex.pdf Faslodex prescribing information]

References